Intrauterine Contraception

This statement provides guidance on antibiotic cover for urgent insertion of intrauterine contraception in women at high risk of STI. Download the full document here.

This statement notes that the Levosert® 52mg LNG-IUS has been licensed for contraceptive use for 6 years. Levosert remains licensed for 5 years for management of heavy menstrual bleeding and is not licensed for endometrial protection as part of HRT.

This statement relates to a field safety notice released by intrauterine device manufacturer Eurogine in 2018 and 2019.

Jaydess® is a levonorgestrel intrauterine system (LNG-IUS) newly launched in the UK for contraception. It is a smaller, lower dose version of the Mirena® LNG-IUS.

This document was updated in March 2019. The FSRH CEU has produced a new product review for Kyleena which summarises the key differences in the product and clinical characteristics between Kyleena and other LNG-IUS available in the UK.

Benilexa® (Gedeon Richter) - a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) with a reloadable one-handed insertion device - is now available in the UK. Benilexa is licensed for 6 years of use for contraception. It is not licensed for endometrial protection as part of HRT. This FSRH CEU Resource provides a table which compares the product characteristics of LNG-IUS devices currently available in the UK, Benilexa®, Levosert®, Mirena®, Kyleena® and Jaydess®.